Genenta Science S.p.A (GNTA) Receivables - Net (2024 - 2025)
Genenta Science S.p.A (GNTA) posted Receivables - Net of $5820.2 for Q4 2025, up 2.83% sequentially from $5659.8 in Q2 2025, and up 8.93% YoY from $5343.0 in Q4 2024.
Genenta Science S.p.A (GNTA) Receivables - Net (2024 - 2025) Analysis & Trends
Genenta Science S.p.A has reported Receivables - Net for 2 years, with the latest figure at $5820.2 in Q4 2025.
- Quarterly Receivables - Net rose 8.93% year-over-year to $5820.2 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5820.2 (up 8.93% YoY) and the FY2025 annual result came in at $5820.2, up 8.93% from the prior year.
- Receivables - Net advanced to $5820.2 in Q4 2025 per GNTA's latest filing, from $5659.8 in the prior quarter.
- Over five years, Receivables - Net peaked at $5820.2 in Q4 2025 and troughed at $5343.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Genenta Science S.p.A | 25.03 Mn | -34.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5,820.22 |
| Dec 31, 2025 | 5,820.22 |
| Jun 30, 2025 | 5,659.80 |
| Jun 30, 2025 | 5,659.80 |
| Dec 31, 2024 | 5,342.98 |
| Dec 31, 2024 | 5,342.98 |
| Jun 30, 2024 | 5,384.44 |
| Jun 30, 2024 | 5,384.44 |